Navigation Links
Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
Date:9/5/2007

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced the extension of a broad antibody development relationship with its licensing partner, Centocor R&D, Inc. The extended relationship provides Centocor with continued access to Medarex's UltiMAb Human Antibody Development System(R) for the generation of fully human antibodies to an unlimited number of targets.

Under the terms of the new agreement, Centocor will license Medarex's UltiMAb(R) technology to discover and potentially develop and commercialize fully human antibody therapeutics. Medarex expects to receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement. No further financial terms of the agreement were disclosed.

Centocor first licensed the UltiMAb technology in 1997, and an expanded agreement was announced in 2000.

"We are delighted with the opportunity to continue our relationship with Centocor," said Howard H. Pien, President and CEO of Medarex. "We have been pleased to be a partner to Centocor in its development of UltiMAb antibodies into potentially very important products, and we look forward to the extension of this partnership into the future."

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Centocor's activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , ... May 04, 2016 , ... PBI-Gordon Corporation is ... Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, after ... a wide variety of roles, ranging from customer service to national product manager, to ...
(Date:5/3/2016)... 2016 The report "Biochips ... Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), ... Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast ... is expected to reach USD 17.75 Billion ... 2015, growing at a CAGR of 18.4% ...
(Date:5/3/2016)... ... ... In a list published by the Boston Business Journal, iLab Solutions ... percentage of the state's 615,000+ small businesses. The list examined companies based in the ... to 2015. , As this award comes on the heels of iLab’s ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently retired ... Corporate Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
Breaking Biology News(10 mins):